These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 29176962)

  • 1. E2F1, a Novel Regulator of Metabolism.
    Denechaud PD; Fajas L; Giralt A
    Front Endocrinol (Lausanne); 2017; 8():311. PubMed ID: 29176962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of E2F1 in mesangial cell proliferation in vitro.
    Inoshita S; Terada Y; Nakashima O; Kuwahara M; Sasaki S; Marumo F
    Kidney Int; 1999 Dec; 56(6):2085-95. PubMed ID: 10594784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TopBP1 recruits Brg1/Brm to repress E2F1-induced apoptosis, a novel pRb-independent and E2F1-specific control for cell survival.
    Liu K; Luo Y; Lin FT; Lin WC
    Genes Dev; 2004 Mar; 18(6):673-86. PubMed ID: 15075294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re-thinking cell cycle regulators: the cross-talk with metabolism.
    Fajas L
    Front Oncol; 2013; 3():4. PubMed ID: 23355973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E2F1-dependent pathways are involved in amonafide analogue 7-d-induced DNA damage, G2/M arrest, and apoptosis in p53-deficient K562 cells.
    Li Y; Shao J; Shen K; Xu Y; Liu J; Qian X
    J Cell Biochem; 2012 Oct; 113(10):3165-77. PubMed ID: 22593008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translating DNA damage into cancer cell death-A roadmap for E2F1 apoptotic signalling and opportunities for new drug combinations to overcome chemoresistance.
    Engelmann D; Pützer BM
    Drug Resist Updat; 2010; 13(4-5):119-31. PubMed ID: 20675184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of the beta1,4-Galactosyltransferase I promoter by E2F1.
    Wei Y; Zhou F; Ge Y; Chen H; Cui C; Liu D; Yang Z; Wu G; Shen J; Gu J; Jiang J
    J Biochem; 2010 Sep; 148(3):263-71. PubMed ID: 20538716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of the G1/S transition phase in mesangial cells by E2F1.
    Inoshita S; Terada Y; Nakashima O; Kuwahara M; Sasaki S; Marumo F
    Kidney Int; 1999 Oct; 56(4):1238-41. PubMed ID: 10504464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic factor EPC1 is a master regulator of DNA damage response by interacting with E2F1 to silence death and activate metastasis-related gene signatures.
    Wang Y; Alla V; Goody D; Gupta SK; Spitschak A; Wolkenhauer O; Pützer BM; Engelmann D
    Nucleic Acids Res; 2016 Jan; 44(1):117-33. PubMed ID: 26350215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of E1AF as a target gene of E2F1-induced apoptosis in response to DNA damage.
    Wei Y; Liu D; Ge Y; Zhou F; Xu J; Chen H; Gu J; Jiang J
    J Biochem; 2008 Oct; 144(4):539-46. PubMed ID: 18687701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E2F1 apoptosis counterattacked: evil strikes back.
    Pützer BM; Engelmann D
    Trends Mol Med; 2013 Feb; 19(2):89-98. PubMed ID: 23219173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic analysis of the combinatorial regulation involving transcription factors and microRNAs in cell fate decisions.
    Yan F; Liu H; Liu Z
    Biochim Biophys Acta; 2014 Jan; 1844(1 Pt B):248-57. PubMed ID: 23845991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Jab1 is a specificity factor for E2F1-induced apoptosis.
    Hallstrom TC; Nevins JR
    Genes Dev; 2006 Mar; 20(5):613-23. PubMed ID: 16481464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel lncRNA, GASL1, inhibits cell proliferation and restricts E2F1 activity.
    Gasri-Plotnitsky L; Ovadia A; Shamalov K; Nizri-Megnaji T; Meir S; Zurer I; Cohen CJ; Ginsberg D
    Oncotarget; 2017 Apr; 8(14):23775-23786. PubMed ID: 28423601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. E2F1-inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis.
    Lizé M; Pilarski S; Dobbelstein M
    Cell Death Differ; 2010 Mar; 17(3):452-8. PubMed ID: 19960022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic control in cancer cells.
    Fajas L
    Ann Endocrinol (Paris); 2013 May; 74(2):71-3. PubMed ID: 23587350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mdm2 inhibition of p53 induces E2F1 transactivation via p21.
    Wunderlich M; Berberich SJ
    Oncogene; 2002 Jun; 21(28):4414-21. PubMed ID: 12080472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo.
    Merdzhanova G; Gout S; Keramidas M; Edmond V; Coll JL; Brambilla C; Brambilla E; Gazzeri S; Eymin B
    Oncogene; 2010 Sep; 29(39):5392-403. PubMed ID: 20639906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation.
    Lin WC; Lin FT; Nevins JR
    Genes Dev; 2001 Jul; 15(14):1833-44. PubMed ID: 11459832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. E2F1 is involved in DNA single-strand break repair through cell-cycle-dependent upregulation of XRCC1 expression.
    Jin R; Sun Y; Qi X; Zhang H; Zhang Y; Li N; Ding W; Chen D
    DNA Repair (Amst); 2011 Sep; 10(9):926-33. PubMed ID: 21757407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.